| Literature DB >> 31743966 |
Eun Lee1, Dae Jin Song2, Woo Kyung Kim3, Dong In Suh4, Hey Sung Baek5, Meeyong Shin6, Young Yoo7, Jin Tack Kim8, Ji Won Kwon9, Gwang Cheon Jang10, Dae Hyun Lim11, Hyeon Jong Yang12, Hwan Soo Kim13, Ju Hee Seo14, Sung Il Woo15, Hyung Young Kim16, Youn Ho Shin17, Ju Suk Lee18, Jisun Yoon19, Sungsu Jung16, Minkyu Han20, Eunjin Eom21, Jinho Yu22.
Abstract
PURPOSE: Childhood asthma has a considerable social impact and economic burden, especially in severe asthma. This study aimed to identify the proportion of childhood asthma severity and to evaluate associated factors for greater asthma severity.Entities:
Keywords: Child; air pollution; asthma; dogs; education status; environmental exposure; risk factor; severity; smoke
Year: 2020 PMID: 31743966 PMCID: PMC6875483 DOI: 10.4168/aair.2020.12.1.86
Source DB: PubMed Journal: Allergy Asthma Immunol Res ISSN: 2092-7355 Impact factor: 5.764
Classification of asthma severity according to NAEPP recommendation*
| Components of severity | Mild intermittent | Mild persistent | Moderate persistent | Severe persistent | ||
|---|---|---|---|---|---|---|
| Impairment | ||||||
| Days with symptoms | ≤ 2 days/week | > 2 days/week, but not daily | Daily | Throughout the day | ||
| Nighttime awakenings | ≤ 2 times/month | 3–4 times/month | > 1 times/week, but not nightly | Often 7 times/week | ||
| Short-acting beta2-agonist use for symptom control | ≤ 2 days/week | > 2 days/week, but not daily† | Daily | Several times per day | ||
| Interference with normal activity | None | Minor limitation | Some limitation | Extremely limited | ||
| Lung function | ||||||
| - FEV1 (predicted) or peak flow (personal best) | Normal FEV1 between exacerbations > 80% | > 80% | 60%–80% | < 60% | ||
| - FEV1/FVC | > 85% | > 80% (≥ 85% in children ≥ 12 years of age) | 75%–80% (FEV1/FVC reduced 5% in children ≥ 12 years of age) | < 75% (FEV1/FVC reduced > 5% in children ≥ 12 years of age) | ||
| Risk | ||||||
| Exacerbations requiring oral systemic corticosteroids (consider severity and interval since last exacerbation) | 0–1 /year | ≥ 2 times/year | - | - | ||
FEV1, forced expiratory volume in 1 second; NAEPP, National Asthma Education and Prevention Program.
*2007 NAEPP Expert Panel Report 3; †In children ≥ 12 years of age, > 2 days/week, but not daily, and more than 1 times on any day.
Demographics of the study population
| Variables | Values | |
|---|---|---|
| Number | 667 | |
| Age (yr) | 8.90 ± 2.59 | |
| Sex (male) | 445/667 (66.7) | |
| Height (cm) | 136.15 ± 15.69 | |
| Weight (kg) | 35.81 ± 14.34 | |
| Body mass index (kg/m2) | 18.56 ± 3.58 | |
| Asthma severity | ||
| Mild intermittent | 251/667 (37.6) | |
| Mild persistent | 260/667 (39.0) | |
| Moderate persistent | 152/667 (22.8) | |
| Severe persistent | 4/667 (0.6) | |
| Positive bronchodilator responses of FEV1 (≥ 12%) | 140/442 (31.7) | |
| Methacholine PC20 (< 16 mg/mL) | 498/498 (100.0) | |
Values are presented as mean ± standard deviation or number (%).
FEV1, forced expiratory volume in 1 second; PC20, cumulative methacholine dose that caused a 20% reduction in FEV1.
Comparisons of baseline characteristics according to the severity of asthma in children
| NAEPP classification | Mild intermittent | Mild persistent | Moderate/severe persistent | Total | Trend | ||
|---|---|---|---|---|---|---|---|
| No. of patients (%) | 251/667 (37.6) | 260/667 (39.0) | 156/667 (23.4) | 667 (100.0) | |||
| Age (yr) | 8.9 ± 2.5 | 8.7 ± 2.5 | 9.5 ± 2.8 | 9.47 ± 4.23 | 0.005 | 0.002 | |
| Sex (male) | 176/251 (70.1) | 159/260 (61.2) | 107/156 (68.6) | 442/667 (66.3) | 0.079 | NA | |
| Gestational age (wk) | 38.6 ± 2.4 | 38.5 ± 2.5 | 38.9 ± 2.2 | 38.6 ± 2.4 | 0.407 | 0.258 | |
| Body mass index (kg/m2) | 18.4 ± 3.6 | 18.4 ± 3.6 | 19.1 ± 3.5 | 18.6 ± 3.6 | 0.078 | 0.042 | |
| Asthma onset age (yr) | 0.011 | < 0.001 | |||||
| < 3 | 50/246 (20.3) | 39/254 (15.4) | 19/152 (12.5) | 108/652 (16.6) | |||
| 3 ≤ age < 6 | 99/246 (40.2) | 80/254 (31.5) | 43/152 (28.3) | 222/652 (34.0) | |||
| 6 ≤ age < 9 | 55/246 (22.4) | 76/254 (29.9) | 49/152 (32.2) | 180/652 (27.6) | |||
| 9 ≤ age < 12 | 32/246 (13.0) | 42/254 (16.5) | 25/152 (16.4) | 99/652 (15.2) | |||
| ≥ 12 | 10/246 (4.1) | 17/254 (6.7) | 16/152 (10.5) | 43/652 (6.6) | |||
| Family history of allergic diseases | 170/246 (69.1) | 183/253 (72.3) | 113/153 (73.9) | 466/652 (28.5) | 0.550 | 0.286 | |
| Parental history of asthma | 37/246 (15.0) | 47/248 (19.0) | 30/153 (19.6) | 114/647 (17.6) | 0.397 | 0.210 | |
| C-section delivery | 35/105 (33.3) | 46/120 (38.3) | 21/47 (44.7) | 102/272 (37.5) | 0.397 | 0.176 | |
| History of bronchiolitis | 98/243 (40.3) | 88/250 (35.2) | 36/151 (23.8) | 222/644 (34.5) | 0.004 | 0.001 | |
| Maternal education level | < 0.001 | < 0.001 | |||||
| ≤ High school | 43/242 (17.8) | 65/253 (25.7) | 58/150 (38.7) | 166/645 (25.7) | |||
| College | 165/242 (68.2) | 168/253 (66.4) | 76/150 (50.7) | 409/645 (63.4) | |||
| Graduate school | 34/242 (14.0) | 20/253 (7.9) | 16/150 (10.7) | 70/645 (10.9) | |||
| Atopy | 192/219 (87.7) | 182/232 (78.4) | 125/139 (89.9) | 499/590 (84.6) | 0.003 | 0.922 | |
| Multi-sensitization (≥ 2 allergens) | 178/219 (81.3) | 164/232 (70.7) | 115/139 (82.7) | 457/590 (77.5) | 0.006 | 0.894 | |
| ACT score | 22.65 ± 3.22 | 20.76 ± 4.37 | 19.07 ± 4.84 | 21.10 ± 4.31 | < 0.001 | < 0.001 | |
| Current FA | 36/249 (14.5) | 24/236 (9.2) | 19/154 (11.9) | 79/663 (11.9) | 0.188 | 0.375 | |
| Current AD | 71/246 (28.9) | 52/252 (20.6) | 45/152 (29.6) | 168/650 (25.8) | 0.053 | 0.843 | |
| Current AR | 188/246 (76.4) | 198/254 (78.0) | 112/152 (73.7) | 498/652 (76.4) | 0.619 | 0.614 | |
| FA diagnosis ever | 64/247 (25.9) | 50/253 (19.8) | 50/154 (32.5) | 164/654 (25.1) | 0.015 | 0.275 | |
| AD diagnosis ever | 110/247 (44.5) | 85/254 (33.5) | 64/154 (41.6) | 259/655 (39.5) | 0.034 | 0.338 | |
| AR diagnosis ever | 206/247 (83.4) | 200/260 (76.9) | 117/155 (75.5) | 523/662 (79.0) | 0.095 | 0.042 | |
Values are presented as mean ± standard deviation or number (%).
NAEPP, National Asthma Education and Prevention Program; NA, not applicable; ACT, Asthma Control Test; FA, food allergy; AD, atopic dermatitis; AR, allergic rhinitis.
*χ2 test; †Linear-by-linear association.
Comparison of environmental factors according to the severity of asthma in children
| NAEPP classification | Mild intermittent | Mild persistent | Moderate/severe persistent | Total | Trend | |
|---|---|---|---|---|---|---|
| Current exposure to ETS at home | 57/246 (23.2) | 86/250 (34.4) | 61/153 (39.9) | 204/649 (31.4) | 0.001 | < 0.001 |
| Presence of any smoker at home | 97/246 (39.4) | 108/251 (43.0) | 72/153 (47.1) | 277/650 (42.6) | 0.321 | 0.132 |
| Usage of air purifier in exposure to high levels of outdoor PM | 132/245 (53.9) | 141/251 (56.2) | 63/153 (41.2) | 336/649 (51.8) | 0.010 | 0.029 |
| Mold exposure in the previous 12 months | 63/244 (25.8) | 74/251 (29.5) | 52/153 (34.0) | 189/648 (29.2) | 0.217 | 0.081 |
| Current mold exposure | 43/244 (17.6) | 46/251 (18.3) | 41/153 (26.8) | 130/648 (20.1) | 0.058 | 0.039 |
| Current cat ownership | 8/246 (3.3) | 12/251 (4.8) | 9/153 (5.9) | 29/350 (4.5) | 0.443 | 0.204 |
| Current dog ownership | 21/246 (8.5) | 38/251 (15.1) | 25/153 (16.3) | 84/650 (12.9) | 0.032 | 0.015 |
| Current dog ownership with sensitization to dog | 2/244 (0.8) | 13/254 (5.1) | 11/151 (7.3) | 26/649 (4.0) | 0.003 | 0.001 |
| Current mold exposure with sensitization to mold ( | 7/214 (3.3) | 6/226 (2.7) | 10/138 (7.2) | 23/578 (4.0) | 0.075 | 0.096 |
NAEPP, National Asthma Education and Prevention Program; ETS, environmental tobacco smoke; PM, particulate matter
*χ2 test; †Linear by linear association.
Comparisons of pulmonary function tests according to severity of asthma in children
| NAEPP classification | Mild intermittent | Mild persistent | Moderate/severe persistent | Overall | Trend | |
|---|---|---|---|---|---|---|
| FEV1, % predicted | ||||||
| Prebronchodilator | 91.52 (79.21–105.75) | 91.59 (77.57–108.15) | 79.61 (57.86–109.53) | < 0.001 | < 0.001 | |
| Postbronchodilator | 97.54 (85.08–111.83) | 97.06 (83.90–112.30) | 82.01 (60.13–111.86) | < 0.001 | < 0.001 | |
| FVC, % predicted | ||||||
| Prebronchodilator | 97.65 (85.34–111.74) | 98.00 (83.88–114.49) | 89.81 (71.16–113.35) | < 0.001 | < 0.001 | |
| Postbronchodilator | 99.21 (86.9–113.28) | 98.96 (85.19–114.97) | 89.68 (71.29–112.81) | < 0.001 | < 0.001 | |
| FEV1/FVC (%) | ||||||
| Prebronchodilator | 93.72 (84.85–103.52) | 93.37 (84.09–103.69) | 88.62 (74.43–105.53) | < 0.001 | < 0.001 | |
| Postbronchodilator | 98.31 (89.31–108.23) | 98.08 (90.38–106.44) | 91.45 (76.91–108.74) | < 0.001 | < 0.001 | |
| MMEF, % predicted | ||||||
| Prebronchodilator | 78.14 (56.89–107.32) | 77.14 (55.67–106.87) | 64.38 (37.47–110.60) | 0.001 | < 0.001 | |
| Postbronchodilator | 101.81 (74.96–138.28) | 95.79 (70.10–130.89) | 72.32 (43.46–120.34) | < 0.001 | < 0.001 | |
| DFEV1 (L) | 0.196 (0.002–19.522) | 0.1827 (0.003–12.775) | 0.254 (0.003–20.671) | < 0.001 | < 0.001 | |
| DFEV1, % predicted | 6.16 (2.59–14.67) | 6.27 (2.61–15.07) | 8.22 (3.36–20.09) | 0.002 | < 0.001 | |
| FeNO (ppb) | 25.15 (12.47–50.73) | 25.77 (12.4–53.53) | 32.44 (15.3–68.76) | 0.010 | 0.003 | |
| Methacholine PC20 (mg/mL) | 2.10 (0.59–7.48) | 2.49 (0.67–9.29) | 1.04 (0.20–5.53) | < 0.001 | < 0.001 | |
Values are presented as geomean ± one standard deviation.
NAEPP, National Asthma Education and Prevention Program; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MMEF, maximal mid-expiratory flow; FeNO, fractional exhaled nitric oxide; ppb, parts per billion; PC20, cumulative methacholine dose that caused a 20% reduction in FEV1.
*Kruskall-Wallis test.
Main effects analysis on asthma severity using multinomial logistic regression
| Factors | Mild intermittent (ref) | Mild intermittent (ref) | ||
|---|---|---|---|---|
| aOR (95% CI) | aOR (95% CI) | |||
| Asthma onset age ≥ 6 years | 1.69 (1.13–2.52) | 0.010 | 1.92 (1.20–3.08) | 0.007 |
| Current exposure to ETS | 1.53 (1.01–2.32) | 0.046 | 1.85 (1.14–2.98) | 0.012 |
| Maternal education level, ≤ High school | 1.47 (0.92–2.35) | 0.106 | 2.32 (1.40–3.86) | 0.001 |
| No usage of air purifier in exposure to high levels of outside PM | 0.97 (0.67–1.43) | 0.897 | 1.76 (1.11–2.77) | 0.016 |
| History of physician-diagnosed bronchiolitis in infancy | 0.88 (0.59–1.31) | 0.523 | 0.53 (0.32–0.88) | 0.014 |
| Current dog ownership with sensitization to dog dander | 5.86 (1.30–26.41) | 0.012 | 6.90 (1.41–33.76) | 0.017 |
Nagelkerke R2=0 .123, χ2=70.978 (P <0.001). Values are presented as aOR (95% CI) from multinomial logistic regression models, related to mild intermittent asthma. Adjusted by age, sex, and a family history of allergic diseases.
aOR, adjusted odds ratio; CI, confidence interval; ETS, environmental tobacco smoke; PM, particulate matter.